Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
STAT+
Health
Biotech
The Readout

Debunking the latest megamerger rumor & the next attempt to treat tinnitus

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Aug. 19, 2016

Reprints
The READOUT
Alex Hogan/STAT

The Readout for August 19, 2016

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

FDA advisory panel recommends conditional approval of Biogen’s drug…
FDA advisory panel recommends conditional approval of Biogen’s drug for rare form of ALS
The lesson biotech absolutely should not take from Silicon…
The lesson biotech absolutely should not take from Silicon Valley Bank’s failure
Some medical students still think black patients feel less…
Some medical students still think black patients feel less pain than whites
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories